Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD1S92)

• Drug Name: Pyrrolo-pyrazine derivative 4 Drug Info
• Synonyms: PMID27774822-Compound-Figure7ExampleI-4
• Cross-matching ID: TTD Drug ID: DMD1S92

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 3 (JAK-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[2]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[3]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[4]
VX-509	DM2U3MX	Rheumatoid arthritis	FA20	Phase 2/3	[5]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[3]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[6]
ATI-502	DM8NODR	Alopecia	ED70	Phase 2	[7]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[8]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[9]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[3]

Drug(s) Targeting Tyrosine-protein kinase SYK (SYK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fostamatinib	DM6AUHV	Immune thrombocytopenic purpura	3B64.13	Approved	[10]
Fostamatinib disodium	DM3274D	Thrombocytopenia	3B64	Phase 3	[11]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[12]
TAK-659	DMJH3U0	Diffuse large B-cell lymphoma	2A81	Phase 2	[13]
GS-9876	DM9Q2B6	Cutaneous lupus erythematosus	EB5Z	Phase 2	[14]
GS-9973	DMKWCTR	Acute myeloid leukaemia	2A60	Phase 2	[15]
Cevidoplenib	DM9QU5G	Rheumatoid arthritis	FA20	Phase 2	[16]
HM43239	DMV1SDA	Acute myeloid leukaemia	2A60	Phase 1/2	[17]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[9]
SKI-O-703	DMTSKXR	Rheumatoid arthritis	FA20	Phase 1	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase SYK (SYK)	TTOU65C	KSYK_HUMAN	Inhibitor	[1]

References

• [1] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
• [5] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [6] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [7] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [9] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Company report (Portola Pharmaceuticals)
• [13] J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
• [16] A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
• [17] Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.